{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:15:10Z","timestamp":1754396110732,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03139-z","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T14:04:07Z","timestamp":1658325847000},"page":"197-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism"],"prefix":"10.1007","volume":"78","author":[{"given":"Matteo","family":"Trevisan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Moneta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianlorenzo","family":"Dionigi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-0982","authenticated-orcid":false,"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"3139_CR1","doi-asserted-by":"publisher","unstructured":"H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara. Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013. JAMA. (2020). https:\/\/doi.org\/10.1001\/jama.2017.2719","DOI":"10.1001\/jama.2017.2719"},{"key":"3139_CR2","doi-asserted-by":"publisher","unstructured":"M. Schlumberger, et al., Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. (2014). https:\/\/doi.org\/10.1016\/S2213-8587(13)70215-8","DOI":"10.1016\/S2213-8587(13)70215-8"},{"key":"3139_CR3","doi-asserted-by":"publisher","unstructured":"M.S. Brose et al., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. (2014). https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9","DOI":"10.1016\/S0140-6736(14)60421-9"},{"key":"3139_CR4","doi-asserted-by":"publisher","unstructured":"M. Schlumberger, et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Eng. J. Med. (2015). https:\/\/doi.org\/10.1056\/NEJMoa1406470","DOI":"10.1056\/NEJMoa1406470"},{"key":"3139_CR5","doi-asserted-by":"publisher","unstructured":"M.S. Brose, et al., Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2021). https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6","DOI":"10.1016\/S1470-2045(21)00332-6"},{"key":"3139_CR6","unstructured":"National Cancer Institute, https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 27 May 2022."},{"key":"3139_CR7","doi-asserted-by":"publisher","unstructured":"J. Pepe, et al., Diagnosis and management of hypocalcemia. Endocrine. (2020). https:\/\/doi.org\/10.1007\/s12020-020-02324-2","DOI":"10.1007\/s12020-020-02324-2"},{"key":"3139_CR8","doi-asserted-by":"publisher","unstructured":"H. Hoftijzer, et al., Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. (2009). https:\/\/doi.org\/10.1530\/EJE-09-0702","DOI":"10.1530\/EJE-09-0702"},{"key":"3139_CR9","doi-asserted-by":"publisher","unstructured":"Y. Luo, et al., Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. Mol. Clin. Oncol. (2014). https:\/\/doi.org\/10.3892\/mco.2013.199","DOI":"10.3892\/mco.2013.199"},{"key":"3139_CR10","doi-asserted-by":"publisher","unstructured":"M.E. Cabanillas, et al., Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J. Clin. Endocrinol. Metab. (2010). https:\/\/doi.org\/10.1210\/jc.2009-1923","DOI":"10.1210\/jc.2009-1923"},{"key":"3139_CR11","doi-asserted-by":"publisher","unstructured":"S.T. Yu, et al., Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Cancer Manag. Res. (2019). https:\/\/doi.org\/10.2147\/CMAR.S191499","DOI":"10.2147\/CMAR.S191499"},{"key":"3139_CR12","doi-asserted-by":"publisher","unstructured":"M.D. Aydemirli, et al., Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data. Eur. J. Endocrinol. (2020). https:\/\/doi.org\/10.1530\/EJE-19-0763","DOI":"10.1530\/EJE-19-0763"},{"key":"3139_CR13","doi-asserted-by":"publisher","unstructured":"A. Berends, et al., Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with \u2018untargeted\u2019 side effects. Acta Oncol. (2020). https:\/\/doi.org\/10.1080\/0284186X.2020.1726455","DOI":"10.1080\/0284186X.2020.1726455"},{"key":"3139_CR14","doi-asserted-by":"publisher","unstructured":"B. Rahmani, et al., Current understanding of tumor lysis syndrome. Hematol. Oncol. (2019). https:\/\/doi.org\/10.1002\/hon.2668","DOI":"10.1002\/hon.2668"},{"key":"3139_CR15","doi-asserted-by":"publisher","unstructured":"S.Z. Imam, M.F. Zahid, M.A. Maqbool. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma. Hematol. Oncol. Stem Cell Ther. (2020). https:\/\/doi.org\/10.1016\/j.hemonc.2018.03.004","DOI":"10.1016\/j.hemonc.2018.03.004"},{"key":"3139_CR16","doi-asserted-by":"publisher","unstructured":"Y. Shimizu, et al., Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report. Clin. J. Gastroenterol. (2021). https:\/\/doi.org\/10.1007\/s12328-020-01306-1","DOI":"10.1007\/s12328-020-01306-1"},{"key":"3139_CR17","doi-asserted-by":"publisher","unstructured":"J.O. Alem\u00e1n, A. Farooki, M. Girotra. Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr. Relat. Cancer. (2014). https:\/\/doi.org\/10.1530\/ERC-12-0400","DOI":"10.1530\/ERC-12-0400"},{"key":"3139_CR18","doi-asserted-by":"publisher","unstructured":"L.K. Laskowski, D.S. Goldfarb, M.A. Howland, K. Kavcsak, D.M. Lugassy, S.W. Smith. A RANKL Wrinkle: Denosumab-induced hypocalcemia. J. Med. Toxicol.: Off. J. Am. Coll. Med. Toxicol. (2016). https:\/\/doi.org\/10.1007\/s13181-016-0543-y","DOI":"10.1007\/s13181-016-0543-y"},{"key":"3139_CR19","doi-asserted-by":"publisher","unstructured":"W.X. Qi, F. Lin, A.N. He, L.N. Tang, Z. Shen, Y. Yao, Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr. Med. Res. Opin. (2013). https:\/\/doi.org\/10.1185\/03007995.2013.813840","DOI":"10.1185\/03007995.2013.813840"},{"key":"3139_CR20","doi-asserted-by":"publisher","unstructured":"K.A. Autio, et al., Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians. Clin. Genitourin. Cancer. (2015). https:\/\/doi.org\/10.1016\/j.clgc.2014.11.008","DOI":"10.1016\/j.clgc.2014.11.008"},{"key":"3139_CR21","doi-asserted-by":"publisher","unstructured":"T. Kamba, et al., VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. (2006). https:\/\/doi.org\/10.1152\/ajpheart.00133.2005","DOI":"10.1152\/ajpheart.00133.2005"},{"key":"3139_CR22","doi-asserted-by":"publisher","unstructured":"Y. Yang, et al. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc. Natl. Acad. Sci. U. S. A. (2013). https:\/\/doi.org\/10.1073\/pnas.1301331110","DOI":"10.1073\/pnas.1301331110"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03139-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:54:35Z","timestamp":1744203275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["3139"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03139-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"27 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"L.F. consults for Eisai and Ipsen; the other authors have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}